Alpha-synuclein modulates retinal iron homeostasis by facilitating the uptake of transferrin-bound iron: Implications for visual manifestations of Parkinson's disease

Free Radical Biology and Medicine

Volumn 97, Issue , 2016, Pages 292-306

  Baksi, Shounak ^a   Tripathi, Ajai K ^a   Singh, Neena ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Parkinson's disease; Retina; Retinal pigment epithelial cells; Transferrin receptor; Transferrin bound iron; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; FERRITIN; TRANSFERRIN; IRON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOSOME; HOMEOSTASIS; HUMAN; HUMAN CELL; IRON TRANSPORT; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RETINA; UPREGULATION; VISUAL DISORDER; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; HOMEOSTASIS; IRON; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGAN SPECIFICITY; PARKINSON DISEASE; RETINA; TRANSFERRIN;

EID: 84978142028     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2016.06.025     Document Type: Article

References (86)

1. [1] Stefanis, L., Alpha-synuclein in Parkinson's disease. Cold Spring Harb. Perspect. Med., 2(2), 2012 a009399.
2. [2] Shulman, J.M., De Jager, P.L., Feany, M.B., Parkinson's disease: genetics and pathogenesis. Annu. Rev. Pathol. 6 (2011), 193–222.
3. [3] Klein, C., Westenberger, A., Genetics of Parkinson's disease. Cold Spring Harb. Perspect. Med., 2(1), 2012 a008888.
4. [4] Venda, L.L., Cragg, S.J., Buchman, V.L., Wade-Martins, R., Alpha-synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci. 33:12 (2010), 559–568.
5. [5] Cookson, M.R., Alpha-synuclein and neuronal cell death. Mol. Neurodegener., 4, 2009, 9.
6. [6] Sauerbier, A., Jenner, P., Todorova, A., Chaudhuri, K.R., Non motor subtypes and Parkinson's disease. Parkinsonism Relat. Disord. 22:Suppl. 1 (2016), S41–S46.
7. [7] Archibald, N.K., Clarke, M.P., Mosimann, U.P., Burn, D.J., The retina in Parkinson's disease. Brain: J. Neurol. 132:Pt 5 (2009), 1128–1145.
8. [8] Armstrong, R.A., Visual symptoms in Parkinson's disease. Parkinsons Dis., 2011, 2011, 908306.
9. [9] Chorostecki, J., Seraji-Bozorgzad, N., Shah, A., Bao, F., Bao, G., George, E., Gorden, V., Caon, C., Frohman, E., Tariq Bhatti, M., Khan, O., Characterization of retinal architecture in Parkinson's disease. J. Neurol. Sci. 355:1–2 (2015), 44–48.
10. [10] Bodis-Wollner, I., Miri, S., Glazman, S., Venturing into the no-man's land of the retina in Parkinson's disease. Mov. Disord. 29:1 (2014), 15–22.
11. [11] Garcia-Martin, E., Satue, M., Otin, S., Fuertes, I., Alarcia, R., Larrosa, J.M., Polo, V., Pablo, L.E., Retina measurements for diagnosis of Parkinson disease. Retina 34:5 (2014), 971–980.
12. [12] Jimenez, B., Ascaso, F.J., Cristobal, J.A., Lopez del Val, J., Development of a prediction formula of Parkinson disease severity by optical coherence tomography. Mov. Disord. 29:1 (2014), 68–74.
13. [13] Archibald, N.K., Clarke, M.P., Mosimann, U.P., Burn, D.J., Retinal thickness in Parkinson's disease. Parkinsonism Relat. Disord. 17:6 (2011), 431–436.
14. [14] Virgili, G., Menchini, F., Casazza, G., Hogg, R., Das, R.R., Wang, X., Michelessi, M., Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst. Rev., 1, 2015 CD008081.
15. [15] Keane, P.A., Mand, P.S., Liakopoulos, S., Walsh, A.C., Sadda, S.R., Accuracy of retinal thickness measurements obtained with Cirrus optical coherence tomography. Br. J. Ophthalmol. 93:11 (2009), 1461–1467.
16. [16] Nguyen-Legros, J., Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease. Surg. Radiol. Anat. 10:2 (1988), 137–144.
17. [17] Tatton, W.G., Kwan, M.M., Verrier, M.C., Seniuk, N.A., Theriault, E., MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells. Brain Res. 527:1 (1990), 21–31.
18. [18] Popova, E., Role of dopamine in distal retina. J. Comp. Physiol. Neuroethol. Sens. Neural Behav. Physiol. 200:5 (2014), 333–358.
19. [19] Martinez-Navarrete, G.C., Martin-Nieto, J., Esteve-Rudd, J., Angulo, A., Cuenca, N., Alpha synuclein gene expression profile in the retina of vertebrates. Mol. Vis. 13 (2007), 949–961.
20. [20] Lashuel, H.A., Overk, C.R., Oueslati, A., Masliah, E., The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14:1 (2013), 38–48.
21. [21] Burre, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M.R., Sudhof, T.C., Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329:5999 (2010), 1663–1667.
22. [22] Burre, J., Sharma, M., Sudhof, T.C., Definition of a molecular pathway mediating alpha-synuclein neurotoxicity. J. Neurosci. 35:13 (2015), 5221–5232.
23. [23] Burre, J., The synaptic function of alpha-synuclein. J. Parkinsons Dis. 5:4 (2015), 699–713.
24. [24] Chutna, O., Goncalves, S., Villar-Pique, A., Guerreiro, P., Marijanovic, Z., Mendes, T., Ramalho, J., Emmanouilidou, E., Ventura, S., Klucken, J., Barral, D.C., Giorgini, F., Vekrellis, K., Outeiro, T.F., The small GTPase Rab11 co-localizes with alpha-synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity. Human Mol. Genet. 23:25 (2014), 6732–6745.
25. [25] Ben Gedalya, T., Loeb, V., Israeli, E., Altschuler, Y., Selkoe, D.J., Sharon, R., Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic 10:2 (2009), 218–234.
26. [26] Cheng, F., Li, X., Li, Y., Wang, C., Wang, T., Liu, G., Baskys, A., Ueda, K., Chan, P., Yu, S., Alpha-synuclein promotes clathrin-mediated NMDA receptor endocytosis and attenuates NMDA-induced dopaminergic cell death. J. Neurochem. 119:4 (2011), 815–825.
27. [27] Perez, R.G., Waymire, J.C., Lin, E., Liu, J.J., Guo, F., Zigmond, M.J., A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 22:8 (2002), 3090–3099.
28. [28] Bendor, J.T., Logan, T.P., Edwards, R.H., The function of alpha-synuclein. Neuron 79:6 (2013), 1044–1066.
29. [29] Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W.H., Castillo, P.E., Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A., Hynes, M., Phillips, H., Sulzer, D., Rosenthal, A., Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25:1 (2000), 239–252.
30. [30] Xiao, W., Shameli, A., Harding, C.V., Meyerson, H.J., Maitta, R.W., Late stages of hematopoiesis and B cell lymphopoiesis are regulated by alpha-synuclein, a key player in Parkinson's disease. Immunobiology 219:11 (2014), 836–844.
31. [31] Ho, C.Y., Troncoso, J.C., Knox, D., Stark, W., Eberhart, C.G., Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients. Brain Pathol. 24:1 (2014), 25–32.
32. [32] Bodis-Wollner, I., Kozlowski, P.B., Glazman, S., Miri, S., Alpha-synuclein in the inner retina in parkinson disease. Ann. Neurol. 75:6 (2014), 964–966.
33. [33] Stover, N.P., Watts, R.L., Spheramine for treatment of Parkinson's disease. Neurotherapeutics 5:2 (2008), 252–259.
34. [34] Yin, F., Tian, Z.M., Liu, S., Zhao, Q.J., Wang, R.M., Shen, L., Wieman, J., Yan, Y., Transplantation of human retinal pigment epithelium cells in the treatment for Parkinson disease. CNS Neurosci. Ther. 18:12 (2012), 1012–1020.
35. [35] Ming, M., Li, X., Fan, X., Yang, D., Li, L., Chen, S., Gu, Q., Le, W., Retinal pigment epithelial cells secrete neurotrophic factors and synthesize dopamine: possible contribution to therapeutic effects of RPE cell transplantation in Parkinson's disease. J. Transl. Med., 7, 2009, 53.
36. [36] Brilliant, M.H., Vaziri, K., Connor, T.B. Jr., Schwartz, S.G., Carroll, J.J., McCarty, C.A., Schrodi, S.J., Hebbring, S.J., Kishor, K.S., Flynn, H.W. Jr., Moshfeghi, A.A., Moshfeghi, D.M., Fini, M.E., McKay, B.S., Mining retrospective data for virtual prospective drug repurposing: l-DOPA and age-related macular degeneration. Am. J. Med. 129:3 (2016), 292–298.
37. [37] Sidhu, A., Wersinger, C., Vernier, P., Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?. FASEB J. 18:6 (2004), 637–647.
38. [38] Ayton, S., Lei, P., Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration. Biomed. Res. Int., 2014, 2014, 581256.
39. [39] Song, D., Dunaief, J.L., Retinal iron homeostasis in health and disease. Front. Aging Neurosci., 5, 2013, 24.
40. [40] Sian-Hulsmann, J., Mandel, S., Youdim, M.B., Riederer, P., The relevance of iron in the pathogenesis of Parkinson's disease. J. Neurochem. 118:6 (2011), 939–957.
41. [41] Lee, H.P., Zhu, X., Liu, G., Chen, S.G., Perry, G., Smith, M.A., Lee, H.G., Divalent metal transporter, iron, and Parkinson's disease: a pathological relationship. Cell Res. 20:4 (2010), 397–399.
42. [42] Lu, Y., Prudent, M., Fauvet, B., Lashuel, H.A., Girault, H.H., Phosphorylation of alpha-Synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of alpha-Synuclein in the pathogenesis of Parkinson's Disease and related disorders. ACS Chem. Neurosci. 2:11 (2011), 667–675.
43. [43] Peng, Y., Wang, C., Xu, H.H., Liu, Y.N., Zhou, F., Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes. J. Inorg. Biochem. 104:4 (2010), 365–370.
44. [44] Davies, P., Moualla, D., Brown, D.R., Alpha-synuclein is a cellular ferrireductase. PLoS One, 6(1), 2011, e15814.
45. [45] Olivares, D., Huang, X., Branden, L., Greig, N.H., Rogers, J.T., Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element. Int. J. Mol. Sci. 10:3 (2009), 1226–1260.
46. [46] Febbraro, F., Giorgi, M., Caldarola, S., Loreni, F., Romero-Ramos, M., Alpha-synuclein expression is modulated at the translational level by iron. Neuroreport 23:9 (2012), 576–580.
47. [47] Golts, N., Snyder, H., Frasier, M., Theisler, C., Choi, P., Wolozin, B., Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J. Biol. Chem. 277:18 (2002), 16116–16123.
48. [48] Paris, I., Martinez-Alvarado, P., Cardenas, S., Perez-Pastene, C., Graumann, R., Fuentes, P., Olea-Azar, C., Caviedes, P., Segura-Aguilar, J., Dopamine-dependent iron toxicity in cells derived from rat hypothalamus. Chem. Res. Toxicol. 18:3 (2005), 415–419.
49. [49] Funke, C., Schneider, S.A., Berg, D., Kell, D.B., Genetics and iron in the systems biology of Parkinson's disease and some related disorders. Neurochem. Int. 62:5 (2013), 637–652.
50. [50] Garcia-Castineiras, S., Iron, the retina and the lens: a focused review. Exp. Eye Res. 90:6 (2010), 664–678.
51. [51] Lozoff, B., Early iron deficiency has brain and behavior effects consistent with dopaminergic dysfunction. J. Nutr. 141:4 (2011), 740S–746S.
52. [52] Bianco, L.E., Wiesinger, J., Earley, C.J., Jones, B.C., Beard, J.L., Iron deficiency alters dopamine uptake and response to L-DOPA injection in Sprague-Dawley rats. J. Neurochem. 106:1 (2008), 205–215.
53. [53] Matak, P., Matak, A., Moustafa, S., Aryal, D.K., Benner, E.J., Wetsel, W., Andrews, N.C., Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice. Proc. Natl. Acad. Sci. USA 113:13 (2016), 3428–3435.
54. [54] Turjanski, N., Lees, A.J., Brooks, D.J., Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 52:5 (1999), 932–937.
55. [55] Moiseyev, G., Takahashi, Y., Chen, Y., Gentleman, S., Redmond, T.M., Crouch, R.K., Ma, J.X., RPE65 is an iron(II)-dependent isomerohydrolase in the retinoid visual cycle. J. Biol. Chem. 281:5 (2006), 2835–2840.
56. [56] He, X., Hahn, P., Iacovelli, J., Wong, R., King, C., Bhisitkul, R., Massaro-Giordano, M., Dunaief, J.L., Iron homeostasis and toxicity in retinal degeneration. Prog. Retin. Eye Res. 26:6 (2007), 649–673.
57. [57] Goralska, M., Ferrell, J., Harned, J., Lall, M., Nagar, S., Fleisher, L.N., McGahan, M.C., Iron metabolism in the eye: a review. Exp. Eye Res. 88:2 (2009), 204–215.
58. [58] Newman, E.A., Müller cells and the retinal pigment epithelium. Albert, D.M., Jakobiec, F.A., (eds.) Principles and Practice of Ophthalmology, 1994, W.B. Saunders Co, Philadelphia, 398–419.
59. [59] Lehmann, G.L., Benedicto, I., Philp, N.J., Rodriguez-Boulan, E., Plasma membrane protein polarity and trafficking in RPE cells: past, present and future. Exp. Eye Res. 126 (2014), 5–15.
60. [60] Leung, K.W., Liu, M., Xu, X., Seiler, M.J., Barnstable, C.J., Tombran-Tink, J., Expression of ZnT and ZIP zinc transporters in the human RPE and their regulation by neurotrophic factors. Investig. Ophthalmol. Vis. Sci. 49:3 (2008), 1221–1231.
61. [61] Hunt, R.C., Davis, A.A., Release of iron by human retinal pigment epithelial cells. J. Cell. Physiol. 152:1 (1992), 102–110.
62. [62] Del Monte, M.A., Rabbani, R., Diaz, T.C., Lattimer, S.A., Nakamura, J., Brennan, M.C., Greene, D.A., Sorbitol, myo-inositol, and rod outer segment phagocytosis in cultured hRPE cells exposed to glucose. In vitro model of myo-inositol depletion hypothesis of diabetic complications. Diabetes 40:10 (1991), 1335–1345.
63. [63] Theurl, M., Song, D., Clark, E., Sterling, J., Grieco, S., Altamura, S., Galy, B., Hentze, M., Muckenthaler, M.U., Dunaief, J.L., Mice with hepcidin-resistant ferroportin accumulate iron in the retina. FASEB J. 30:2 (2016), 813–823.
64. [64] Kohgo, Y., Ikuta, K., Ohtake, T., Torimoto, Y., Kato, J., Body iron metabolism and pathophysiology of iron overload. Int. J. Hematol. 88:1 (2008), 7–15.
65. [65] Rahman, Y.E., Cerny, E.A., Lau, E.H., Carnes, B.A., Enhanced iron removal from liver parenchymal cells in experimental iron overload: liposome encapsulation of HBED and phenobarbital administration. Blood 62:1 (1983), 209–213.
66. [66] Li, H., Ginzburg, Y.Z., Crosstalk between iron metabolism and erythropoiesis. Adv. Hematol., 2010, 2010, 605435.
67. [67] Wang, C.Y., Jenkitkasemwong, S., Duarte, S., Sparkman, B.K., Shawki, A., Mackenzie, B., Knutson, M.D., ZIP8 is an iron and zinc transporter whose cell-surface expression is up-regulated by cellular iron loading. J. Biol. Chem. 287:41 (2012), 34032–34043.
68. [68] Liuzzi, J.P., Aydemir, F., Nam, H., Knutson, M.D., Cousins, R.J., Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. Proc. Natl. Acad. Sci. USA 103:37 (2006), 13612–13617.
69. [69] Ponka, P., Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood 89:1 (1997), 1–25.
70. [70] Garrick, M.D., Garrick, L.M., Loss of rapid transferrin receptor recycling due to a mutation in Sec15l1 in hbd mice. Biochim. Biophys. Acta 1773:2 (2007), 105–108.
71. [71] Dexter, D.T., Carayon, A., Javoy-Agid, F., Agid, Y., Wells, F.R., Daniel, S.E., Lees, A.J., Jenner, P., Marsden, C.D., Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain: J. Neurol. 114:Pt 4 (1991), 1953–1975.
72. [72] Connor, J.R., Snyder, B.S., Arosio, P., Loeffler, D.A., LeWitt, P., A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 65:2 (1995), 717–724.
73. [73] Gravotta, D., Carvajal-Gonzalez, J.M., Mattera, R., Deborde, S., Banfelder, J.R., Bonifacino, J.S., Rodriguez-Boulan, E., The clathrin adaptor AP-1A mediates basolateral polarity. Dev. Cell 22:4 (2012), 811–823.
74. [74] Ugarte, M., Osborne, N.N., Brown, L.A., Bishop, P.N., Iron, zinc, and copper in retinal physiology and disease. Surv. Ophthalmol. 58:6 (2013), 585–609.
75. [75] Odorizzi, G., Trowbridge, I.S., Structural requirements for basolateral sorting of the human transferrin receptor in the biosynthetic and endocytic pathways of Madin-Darby canine kidney cells. J. Cell Biol. 137:6 (1997), 1255–1264.
76. [76] Gonzalez, A., Rodriguez-Boulan, E., Clathrin and AP1B: key roles in basolateral trafficking through trans-endosomal routes. FEBS Lett. 583:23 (2009), 3784–3795.
77. [77] Perez Bay, A.E., Schreiner, R., Benedicto, I., Rodriguez-Boulan, E.J., Galectin-4-mediated transcytosis of transferrin receptor. J. Cell Sci. 127:Pt 20 (2014), 4457–4469.
78. [78] Perez Bay, A.E., Schreiner, R., Mazzoni, F., Carvajal-Gonzalez, J.M., Gravotta, D., Perret, E., Lehmann Mantaras, G., Zhu, Y.S., Rodriguez-Boulan, E.J., The kinesin KIF16B mediates apical transcytosis of transferrin receptor in AP-1B-deficient epithelia. EMBO J. 32:15 (2013), 2125–2139.
79. [79] Kubo, K., Kobayashi, M., Nozaki, S., Yagi, C., Hatsuzawa, K., Katoh, Y., Shin, H.W., Takahashi, S., Nakayama, K., SNAP23/25 and VAMP2 mediate exocytic event of transferrin receptor-containing recycling vesicles. Biol. Open 4:7 (2015), 910–920.
80. [80] Takahashi, S., Kubo, K., Waguri, S., Yabashi, A., Shin, H.W., Katoh, Y., Nakayama, K., Rab11 regulates exocytosis of recycling vesicles at the plasma membrane. J. Cell Sci. 125:Pt 17 (2012), 4049–4057.
81. [81] Gitler, A.D., Bevis, B.J., Shorter, J., Strathearn, K.E., Hamamichi, S., Su, L.J., Caldwell, K.A., Caldwell, G.A., Rochet, J.C., McCaffery, J.M., Barlowe, C., Lindquist, S., The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc. Natl. Acad. Sci. USA 105:1 (2008), 145–150.
82. [82] Eisbach, S.E., Outeiro, T.F., Alpha-synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology. J. Mol. Med. 91:6 (2013), 693–703.
83. [83] Chua, C.E., Tang, B.L., Rabs, SNAREs and alpha-synuclein--membrane trafficking defects in synucleinopathies. Brain Res. Rev. 67:1–2 (2011), 268–281.
84. [84] Vargas, K.J., Makani, S., Davis, T., Westphal, C.H., Castillo, P.E., Chandra, S.S., Synucleins regulate the kinetics of synaptic vesicle endocytosis. J. Neurosci. 34:28 (2014), 9364–9376.
85. [85] Pelham, C., Jimenez, T., Rodova, M., Rudolph, A., Chipps, E., Islam, M.R., Regulation of HFE expression by poly(ADP-ribose) polymerase-1 (PARP1) through an inverted repeat DNA sequence in the distal promoter. Biochim. Biophys. Acta 1829:12 (2013), 1257–1265.
86. [86] Fader, C.M., Colombo, M.I., Autophagy and multivesicular bodies: two closely related partners. Cell Death Differ. 16:1 (2009), 70–78.